Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023

Rothschedl, E. and Wolf, S. (2022): Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023. Fact Sheet Nr. 113.

[thumbnail of Fact Sheet Nr.113_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
126kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 470-480 Cervix uteri. Cervix diseases
Language:	English
Series Name:	Fact Sheet Nr. 113
Deposited on:	03 Nov 2022 16:24
Last Modified:	06 Mar 2023 16:50

Repository Staff Only: item control page